promo_leaderboard Ad
‹ All stocks
MBX

MBX Biosciences, Inc. Common Stock

MBX · NASDAQ · Healthcare
$52.25
▼ $0.87 (-1.63%)
$52.25 $52.49 $52.72 $52.95 $52.25 21:33 15:03
Day range
$51.98 – $54.01
Year range
$24.68 – $72.64
Open
$53.28
Previous close
$53.12
Market cap
$2.59B
Volume (24h)
$21.6K
Volume (52w)
$1.13M
Performance
7D
▼ -7.24%
1M
▼ -0.43%
3M
▼ -23.61%
6M
▲ 64.37%
1Y
▲ 104.04%
YTD
▲ 71.04%
3Y
▲ 120.95%
5Y
▲ 120.95%
All-time
▲ 120.95%
Key statistics
P/E ratio
-17.02
EPS (TTM)
$-3.07
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
49.7M
About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Visit website
Country: United States of America
More in Healthcare